Saturday 17 October 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024. Insiders bought in the last twelve months.
21.10
0.10
+0.48%
Follow APLM
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | 0.00% | 0.00% | |
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(126.76) | (112.33) | (95.50) | (62.67) | |
Capital Expenditures |
(0.34) | 0.01 | 0.06 | 0.06 | |
| Other line items | |||||
Cash ROIC |
(252.29%) | (767.81%) | 4,145.14% | (71,213.64%) | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
16.13 | 3.08 | 137.20 | 5.44 | |
Capex/Depreciation |
(0.17) | 0.00 | 0.04 | 0.06 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026